Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
789 results about "Cancer drugs" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
There are many different types of drugs that are used to treat cancer. Some of the drugs used to treat cancer are chemotherapy drugs, biological agents, and hormone therapy drugs. The drugs used to treat cancer ultimately depend on the type of cancer and the stage of the disease.
Methods for stratifying and annotating cancer drug treament options
ActiveUS20110230360A1Microbiological testing/measurementPreparing sample for investigationCancer pharmacotherapyCancer drugs
Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
Owner:BLOODQ INC
Compositions and methods for the treatment of cancer
InactiveUS20020128228A1Reducing and avoiding adverse effectImprove toleranceBiocideAnimal repellantsIntestinal structureCancer prevention
This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Treatment of cancer with 2-deoxyglucose
Owner:THRESHOLD PHARM INC
Expression Profile Of Prostate Cancer
InactiveUS20080222741A1Improve concentrationIncrease concentrationCompound screeningApoptosis detectionCancer drugsProstate cancer
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.
Owner:RGT UNIV OF MICHIGAN
Expressed profile of thyroid cancer
InactiveUS20080044824A1Microbiological testing/measurementBiological material analysisCancer drugsBiology
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.
Owner:UNIVERSITY OF CINCINNATI
Expression profile of prostate cancer
InactiveUS7229774B2Reduce proliferationInhibit expressionMicrobiological testing/measurementDepsipeptidesCancer drugsProstate cancer
Owner:RGT UNIV OF MICHIGAN
Expression profile of prostate cancer
InactiveUS20060211017A1Reduce proliferationInhibit expressionMicrobiological testing/measurementRecombinant DNA-technologyCancer drugsProstate cancer
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.
Owner:RGT UNIV OF MICHIGAN
Therapeutic material delivery system for tissue voids and cannulated implants
ActiveUS20100125240A1Minimal disruptionRemoved positioningBone implantInfusion syringesBone cementProgenitor cell
Described herein is a novel drug delivery assembly having particular applicability to the field of orthopedic and surgical medicine. The devices and assemblies described herein enable the efficient application and retention of potentially expensive therapeutic materials to very specific locations, particularly those associated with voids in bone and tissue. One particularly unique aspect of the present invention involves the introduction of constructs which promote the retention of therapeutic material in the target area of application for beneficial use, for example by forming a proximal barrier that prevents leakage of the therapeutic material out of the target area. Additionally, the present invention provides unique devices and methods for surgical introduction of such constructs. The present invention finds particular application in connection with introduction of stem and progenitor cells, bioactive molecules and bone scaffold materials in conjunction with bone voids and with the use of cannulated implants, such as bone screws (also surgical screws) and pins. The present invention also has beneficial use in the delivery of cancer drugs, antimicrobials, bone cements and other therapeutic materials.
Owner:BIOACTIVE SURGICAL
Ido inhibitors
Owner:NEWLINK GENETICS
Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
InactiveUS7445794B1BiocideImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenCarboxylic acid
The present invention generally relates to systems and methods for treating inflammatory and proliferative diseases, and wounds, using a combination of (1) fatty acid metabolism inhibitors and (2) glycolytic inhibitors and / or UCP and / or Fas inhibitors or antibodies. More particularly, the invention combines an oxirane carboxylic acid compound, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and / or an antibody against UCP and / or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers (i.e., cancers resistant to conventional cancer drug therapies).
Owner:UNIV OF COLORADO THE REGENTS OF
Methods for stratifying and annotating cancer drug treatment options
ActiveUS8583380B2Microbiological testing/measurementBiological testingCancer pharmacotherapyCancer drugs
Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
Owner:BLOODQ INC
Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
InactiveUS20090155212A1Reduce development riskOrganic active ingredientsPeptide/protein ingredientsTime scheduleCancer drugs
The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.
Owner:BRATZLER ROBERT L +1
Expression profile of thyroid cancer
InactiveUS7598052B2Microbiological testing/measurementBiological material analysisCancer drugsBiology
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.
Owner:UNIVERSITY OF CINCINNATI
Sphaelactone derivatives, their pharmaceutical compositions, preparation method thereof and application thereof
ActiveCN102234259AStrong inhibitory activityGood killing effectOrganic active ingredientsOrganic chemistryDrugDisease
The present invention relates to sphaelactone derivatives, their pharmaceutical compositions, a preparation method thereof and application thereof, and especially relates to a sphaelactone derivative pharmaceutical compound which is represented by a formula (I) and is used for treating cancer diseases, pharmaceutical compositions containing an effective amount of the sphaelactone derivative pharmaceutical compound represented by the formula (I) and pharmaceutically acceptable carrier or pharmaceutical compositions with other anti-cancer medicine, a preparation method of a sphaelactone derivative, and application of the sphaelactone derivative in medicine, especially application in preparation of medicines for treating cancer diseases.
Owner:ACCENDATECH +1
Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an anti-cancer agent and an IGF1R inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The IGF1R inhibitor is represented by Formula I: wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein.
Owner:OSI PHARMA INC
Cancer Marker and Therapeutic Target
InactiveUS20100278844A1Permit stratificationConvenient treatmentOrganic active ingredientsAntibody ingredientsOncologyDrug biological activity
Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and / or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL 17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL 17 and CCL22 provide anti-cancer agents.
Owner:CANCER RES TECH LTD
Compositions and methods for treatment for neoplasms
InactiveCN101217956AAntineoplastic agentsHeterocyclic compound active ingredientsCancer drugsNeoplasm
Owner:COMBINATORX
Piperlongumine derivatives and medicinal composition and application to preparation of medicament for inhibiting tumor growth thereof
The invention provides application of piperlongumine derivatives to the preparation of a medicament for treating a cancer and a medicinal composition which uses the piperlongumine derivatives as active ingredients and can be used for treating the cancer. The invention provides various piperlongumine derivatives which are extracted from natural plants and are synthetized artificially. Experiments prove that the compounds can be used for selectively killing cancer cells without influencing the physiological functions of normal cells, and animal in-vivo experiments prove that the compounds can be used for obviously inhibiting tumor growth without influencing the normal physiological functions of animals so as to show that the compounds can be used for preparing the novel anti-cancer medicament capable of selectively killing the cancer cells.
Owner:LAIYI TECH DEV XINCHANG COUNTY
Use of piperlongumine derivatives in preparation of medicines for treating cancers and medicinal compositions thereof
The invention discloses the use of piperlongumine derivatives in the preparation of medicines for treating cancers and anticancer medicinal compositions taking the piperlongumine derivatives as active ingredients. The invention provides several piperlongumine derivatives, which are extracted from natural plants and synthesized artificially. Experiments prove that these compounds can selectively kill cancer cells without influencing the physiological functions of normal cells. Animal in-vivo experiments prove that these compounds can obviously suppress the growth of tumors without influencing the normal physiological functions of animals. Thus, these compounds can be used for preparing new anticancer medicines capable of killing cancer cells selectively.
Owner:李绍路
Nitrobenzyl derivatives of Anti-cancer agents
Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
PendingUS20170224818A1Reduce releasePrevent adverse side effectsRadioactive preparation carriersMammal material medical ingredientsBispecific antibodyTrifunctional antibody
The present invention relates to the use of T cell redirecting, bispecific, in particular trifunctional, antibodies for the treatment of a cancer disease, wherein said antibody is administered via the subcutaneous route. Thereby, the release of proinflammatory cytokines is reduced and, simultaneously, the release of inhibitory cytokines is substantially suppressed. That treatment by bispecific, in particular trifunctional, antibodies may be combined in a combination therapy with other anti-cancer drugs.
Owner:LINDIS BIOTECH GMBH
Active extracts of rosa roxburghii tratt fruit, and preparation method, detection method and application thereof
ActiveCN102145062AQuality assuranceSignificant anti-cancer activityComponent separationMetabolism disorderAlgluceraseAnti cancer drugs
The invention discloses active extracts of rosa roxburghii tratt fruit, and a preparation method, a detection method and application thereof. The preparation method comprises the following steps of: extracting rosa roxburghii tratt fruit by conventional processes; filtering to remove rosa roxburghii tratt residues; concentrating the filtered solution at the reduced pressure; extracting with an organic solvent; recovering the organic solvent; adding water for dispersing; filtering; washing with water for depositing; mixing the filtered solutions; and respectively drying the filtered solution and the deposit to respectively obtain an active extract B and an active extract A. The preparation method provided by the invention solves the problems of extraction, enrichment and refinement of effective active components in the rosa roxburghii tratt, and industrial production is easy to realize by the preparation process; the detection method provided by the invention can effectively ensure thequality of the active extracts; and the obtained active extracts have obvious anti-malignant tumor activity, have synergistic action with clinical anti-cancer drugs, have better alpha-glucosidase inhibition activity, can be used for preparing drugs and adjuvant drugs for treating malignant tumors or used as health food additives, can also be used for preparing drugs and health products for preventing or treating diabetes or used as food additives, and have higher application values and good application prospects.
Owner:THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
Biological chips of surface plasma resonating biological sensor, preparation and application
The invention relates to a cell surface receptor biochip based on a surface plasmon resonance biosensor, a preparation method and application thereof. The biochip is characterized in that the chip is provided with a gold surface coating at a glass substrate and the gold surface is fixed with a sephadex layer which is fixed with the monoclonal antibody of the Beta subunit of the receptors of anti para-insulin and surface receptors are fixed by antibody capture. The preparation method includes that the monoclonal antibody of the Beta subunit of the receptors of anti para-insulin adopts the method of antibody capture and is fixed on the surface of CM5 chip based on the surface plasmon resonance biosensor, so as to produce the protein chip of para-insulin receptors which is applicable to the mutual action between IGF-1R and IRS-1, SHC, PI3K or GRB2 and hopeful to be applied to screening cancer-fighting drugs.
Owner:SHANGHAI INST OF MICROSYSTEM & INFORMATION TECH CHINESE ACAD OF SCI +1
Spiro-substituted pyrimido-cyclic compound, and preparation method and medical application thereof
The invention discloses a spiro-substituted pyrimido-cyclic compound with selective inhibition effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound or a prodrug thereof; the spiro-substituted pyrimido-cyclic compound is represented by a formula (I), and the definition of each group or symbol in the formula is shown in the specification in detail.In addition, the invention also discloses a pharmaceutical composition containing the compound and an application of the compound in preparation of cancer drugs.
Owner:GENFLEET THERAPEUTICS (SHANGHAI) INC +1
Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and / or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1 / PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and / or nanoparticle formulations.
Owner:UNIVERSITY OF CHICAGO
Cancer drug delivery using modified transferrin
InactiveUS20090181048A1Strengthen associationIncreased cellular internalizationBacterial antigen ingredientsTransferrinsAnticarcinogenCancer cell
Owner:UNIVERSITY OF VERMONT
Multi-drug liposomes to treat tumors
InactiveUS20120231066A1Increase the number ofWithout compromising safetyAntineoplastic agentsLiposomal deliveryAbnormal tissue growthCancer cell
A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromising the safety of the patient. The stabilized multi-drug liposomes are designed to extravasate thru “leaky” blood capillaries supplying the tumor and enter the tumor tissue where they will accumulate over time and ultimately released to kill surrounding tumor cells. The multi-drug liposomes are likewise unable to extravasate thru normal blood capillaries and will thus be less toxic to normal tissues.
Owner:SMITH HENRY JOHN +1
Cytotoxin T lymphocyte
InactiveCN1379041AGood effectEfficient detectionPeptide/protein ingredientsMicrobiological testing/measurementProstate cancerT lymphocyte
PURPOSE: Provided are a method and a substance useful for treatment and diagnosis of prostate cancer. Particularly, provided are a peptide having a specific sequence, a mutant thereof and a nucleic acid encoding the same. CONSTITUTION: An HLA-A24- restricted antigen peptide is characterized by being capable of inducing a CTL(cytotoxic lymphocyte) having a T cell receptor specifically recognizing a cell manifesting on the cell surface a complex between the peptide and HLA(human main histocompatibility antigen)-A24 molecule.
Owner:TAKARA HOLDINGS
Substituted heteroaromatic ring dihydropyrimidinone derivative as well as preparation method and medical application thereof
ActiveCN112390818AHigh activityGood choiceOrganic active ingredientsOrganic chemistry methodsGenes mutationPharmaceutical medicine
The invention discloses a substituted heteroaromatic ring dihydropyrimidinone derivative with selective inhibition effect on KRAS gene mutation or a pharmaceutically acceptable salt, a stereoisomer, asolvate or a prodrug thereof. The substituted heteroaromatic ring dihydropyrimidinone derivative is shown as a formula (I), and each group in the formula is as defined in the specification. In addition, the invention also discloses a pharmaceutical composition containing the compound and application of the compound in preparation of cancer drugs.
Owner:GENFLEET THERAPEUTICS (SHANGHAI) INC +1
1-substituted-4,4-2 substituted thiosemicarbazide compounds, production method and uses of the same
InactiveCN101195597AStrong anti-cell proliferation effectOrganic chemistryAntineoplastic agentsIntestinal CancerAdenocarcinoma lung cancer
The invention relates to a 1-substituted-4, 4-bis-substituted thiosemicarbazide compound, a relative preparation method and application thereof, wherein the compound is represented as formula I, R1, R2 and R3 are defined as description. The inventive compound can restrain A-549 (human lung adenocarcinoma), P388 (mouse leukemia cell line), and HT-29 (human intestinal cancer cell line), with strong inhibition of cell proliferation, which can be used to develop new anti-cancer drug.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com